Journal: The Journal of Pathology: Clinical Research

Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

doi: 10.1002/cjp2.163

Figure Lengend Snippet: Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 FGFR+ patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; CTA, clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.

Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

Techniques: Selection, Diagnostic Assay

Journal: The Journal of Pathology: Clinical Research

Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

doi: 10.1002/cjp2.163

Figure Lengend Snippet: Concordance analysis for CDx and CTA (reference) FGFR gene mutation screening methods

Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

Techniques: Mutagenesis

Journal: The Journal of Pathology: Clinical Research

Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

doi: 10.1002/cjp2.163

Figure Lengend Snippet: Investigator‐assessed ORR in erdafitinib‐treated patients who were FGFR+ by both CDx and CTA assays

Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

Techniques:

Journal: The Journal of Pathology: Clinical Research

Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

doi: 10.1002/cjp2.163

Figure Lengend Snippet: Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 FGFR+ patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; CTA, clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.

Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

Techniques: Selection, Diagnostic Assay

Journal: The Journal of Pathology: Clinical Research

Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

doi: 10.1002/cjp2.163

Figure Lengend Snippet: Concordance analysis for CDx and CTA (reference) FGFR gene mutation screening methods

Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

Techniques: Mutagenesis

Journal: The Journal of Pathology: Clinical Research

Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

doi: 10.1002/cjp2.163

Figure Lengend Snippet: Investigator‐assessed ORR in erdafitinib‐treated patients who were FGFR+ by both CDx and CTA assays

Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

Techniques: